Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
Abigail Lewis, Content Intern
Advertisement
Contact me!
Articles by Abigail Lewis, Content Intern
ARPA-H funds OCULAB to build tear-duct sensors that track biomarkers in real time and microdose drugs, transforming dry-eye and systemic care.
New phase 3 trial tests rhNGF eye drops for persistent corneal epithelial defects, aiming for full healing and a first approved PCED therapy.
New findings confirm TearCare's long-term effectiveness for dry eye disease, showing significant patient improvements with minimal treatments over 2 years.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities
2
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
3
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
4
iOpeners with Nicole Bajic, MD: Nikolina Budimlija, MD, on building a multidisciplinary dry eye clinic in Ireland
5